Home/Pipeline/ALN-APP

ALN-APP

Alzheimer's Disease

Phase 1Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1

Status

Active

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.

View full company profile

Therapeutic Areas

Rare Diseases Genetic Disorders Amyloidosis Porphyria Primary Hyperoxaluria Cardiovascular Neurology

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
Donanemab	Eli Lilly	Phase 3	Regulatory Review
Alzheimer's Disease Program	Roche	Various	Active
UCB0022	UCB	Phase 1	Active
Lecanemab (Leqembi)	Eisai	Commercial	Approved
ARO-MAPT	Arrowhead Pharmaceuticals	Pre-clinical	Active
AMBAR®	Grifols	Clinical	Active
Lu AG08854 (L1CAM mAb)	Lundbeck	Preclinical	Research stage
DNL919	Denali Therapeutics	Phase 1b	Active
BAN2802	BioArctic AB	Preclinical	Back-up candidate
Lecanemab SC	BioArctic AB	Phase 3	Active (Study 302)
Undisclosed Program	uniQure	Preclinical	Research
NVG-291	NervGen Pharma	Phase 1b/2a	Active, not yet recruiting